Table of Contents Author Guidelines Submit a Manuscript
Advances in Bioinformatics
Volume 2014, Article ID 431696, 7 pages
http://dx.doi.org/10.1155/2014/431696
Research Article

In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer

Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, Jalan Menara Gading 1, Taman Connaught, Cheras, 56000 Kuala Lumpur, Malaysia

Received 6 February 2014; Accepted 19 August 2014; Published 21 September 2014

Academic Editor: Tatsuya Akutsu

Copyright © 2014 Ayesha Fatima and H. F. Yee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. A. Omar, Z. M. Ali, and S. I. Tamin Nor, Eds., Malaysian Cancer Statistics—Data and Figure Penisular Malysia, National Cancer Registry Ministry of Health Malaysia, 2006.
  2. National Cancer Society Malaysia, http://cancer.org.my/learn-about-cancer/about-cancer/.
  3. G. C. C. Lim, “Overview of cancer in Malaysia,” Japanese Journal of Clinical Oncology, vol. 32, pp. S37–S42, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Mohan, S. I. Abdelwahab, S.-C. Cheah et al., “Apoptosis effect of girinimbine isolated from Murraya koenigii on lung cancer cells in vitro,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 689865, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-K. Liam, M. I. A. Wahid, P. Rajadurai, Y.-K. Cheah, and T. S.-Y. Ng, “Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients,” Journal of Thoracic Oncology, vol. 8, no. 6, pp. 766–772, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. The American Cancer Society, “Learn about cancer,” http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer.
  7. A. Fernández-Medarde and E. Santos, “Ras in cancer and developmental diseases,” Genes and Cancer, vol. 2, no. 3, pp. 344–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. M. K. Westcott and M. D. To, “The genetics and biology of KRAS in lung cancer,” Chinese Journal of Cancer, vol. 32, no. 2, pp. 63–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. V. Milburn, L. Tong, A. M. Devos et al., “Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins,” Science, vol. 247, no. 4945, pp. 939–945, 1990. View at Publisher · View at Google Scholar · View at Scopus
  10. D. A. Eberhard, B. E. Johnson, L. C. Amler et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5900–5909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. T. Brünger, M. V. Milburn, L. Tong et al., “Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 12, pp. 4849–4853, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Massarelli, M. Varella-Garcia, X. Tang et al., “KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer,” Clinical Cancer Research, vol. 13, no. 10, pp. 2890–2896, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-S. Chang, K.-T. Yeh, N. C. Hsu, S.-H. Lin, T.-J. Chang, and J.-G. Chang, “Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension,” Clinical Biochemistry, vol. 43, no. 3, pp. 296–301, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-J. Yang, C.-K. Hsu, H.-J. Chang et al., “The KRAS mutation is highly correlated with EGFR alterations in patients with non-small cell lung cancer,” Fooyin Journal of Health Sciences, vol. 1, no. 2, pp. 65–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Riely, J. Marks, and W. Pao, “KRAS mutations in non-small cell lung cancer,” Proceedings of the American Thoracic Society, vol. 6, no. 2, pp. 201–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Jančík, J. Drábek, D. Radzioch, and M. Hajdúch, “Clinical relevance of KRAS in human cancers,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 150960, 13 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Dienstmann, S. De Dosso, E. Felip, and J. Tabernero, “Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer,” Molecular Oncology, vol. 6, no. 1, pp. 15–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Soria, T. S. Mok, F. Cappuzzo, and P. A. Jänne, “EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects,” Cancer Treatment Reviews, vol. 38, no. 5, pp. 416–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Ulivi, D. Calistri, W. Zoli, and D. Amadori, “Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects,” Journal of Nucleic Acids Investigation, vol. 1, no. 1, pp. 47–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Stella, M. Luisetti, S. Inghilleri et al., “Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies,” Respiratory Medicine, vol. 106, no. 2, pp. 173–183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-F. Hsu, K.-H. Huang, K.-J. Lu et al., “Typhonium blumei extract inhibits proliferation of human lung adenocarcinoma A549 cells via induction of cell cycle arrest and apoptosis,” Journal of Ethnopharmacology, vol. 135, no. 2, pp. 492–500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. S. Lai, R. H. M. H. Mas, N. K. Nair, S. M. Mansor, and V. Navaratnam, “Chemical constituents and in vitro anticancer activity of Typhonium flagelliforme (Araceae),” Journal of Ethnopharmacology, vol. 127, no. 2, pp. 486–494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-S. Lai, R. H. M. H. Mas, N. K. Nair, M. I. A. Majid, S. M. Mansor, and V. Navaratnam, “Typhonium flagelliforme inhibits cancer cell growth in vitro and induces apoptosis: an evaluation by the bioactivity guided approach,” Journal of Ethnopharmacology, vol. 118, no. 1, pp. 14–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Maurer, L. S. Garrenton, A. Oh et al., “Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 14, pp. 5299–5304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. B. J. Grant, S. Lukman, H. J. Hocker et al., “Novel allosteric sites on ras for lead generation,” PLoS ONE, vol. 6, no. 10, Article ID e25711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Shima, Y. Yoshikawa, M. Ye et al., “In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 20, pp. 8182–8187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Trott and A. J. Olson, “Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, and K. M. Shokat, “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions,” Nature, vol. 503, no. 7477, pp. 548–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. G. M. Morris, D. S. Goodsell, R. S. Halliday et al., “Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function,” Journal of Computational Chemistry, vol. 19, no. 14, pp. 1639–1662, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Morris and R. Huey, “AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, pp. 2785–2791, 2009. View at Google Scholar
  31. R. Huey, G. M. Morris, and S. Forli, Using AutoDock 4 and Vina with AutoDockTools: A Tutorial, 2011.
  32. D. Seeliger and B. L. de Groot, “Ligand docking and binding site analysis with PyMOL and Autodock/Vina,” Journal of Computer-Aided Molecular Design, vol. 24, no. 5, pp. 417–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. ACD/ChemSketch, Version 12, Advanced Chemistry Development, ACD/ChemSketch, Toronto, Canada, 2014, http://www.acdlabs.com/.
  34. S. Mohan, A. B. Abdul, S. I. Abdelwahab et al., “Typhonium flagelliforme induces apoptosis in CEMss cells via activation of caspase-9, PARP cleavage and cytochrome c release: its activation coupled with G0/G1 phase cell cycle arrest,” Journal of Ethnopharmacology, vol. 131, no. 3, pp. 592–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. Boriack-Sjodin, S. M. Margarit, D. Bar-Sagi, and J. Kuriyan, “The structural basis of the activation of Ras by Sos,” Nature, vol. 394, no. 6691, pp. 337–343, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. A. G. Taveras, S. W. Remiszewski, R. J. Doll et al., “Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex,” Bioorganic and Medicinal Chemistry, vol. 5, no. 1, pp. 125–133, 1997. View at Publisher · View at Google Scholar · View at Scopus